Provided by Tiger Trade Technology Pte. Ltd.

Warrior Met Coal LLC

94.91
-2.8600-2.93%
Volume:36.90K
Turnover:3.50M
Market Cap:4.99B
PE:22.81
High:96.03
Open:96.03
Low:93.89
Close:97.77
52wk High:111.42
52wk Low:57.53
Shares:52.57M
Float Shares:51.78M
Volume Ratio:0.93
T/O Rate:0.07%
Dividend:0.32
Dividend Rate:0.34%
EPS(TTM):4.16
EPS(LYR):1.08
ROE:10.04%
ROA:5.17%
PB:2.18
PE(LYR):87.88

Loading ...

Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson

GlobeNewswire
·
Jun 22

Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026

GlobeNewswire
·
Jun 17

Warrior Met Coal Is Maintained at Buy by B. Riley Securities

Dow Jones
·
Jun 11

Warrior Met Coal Inc : B. Riley Raises Target Price to $123 From $117

THOMSON REUTERS
·
Jun 10

B. Riley Raises Price Target on Warrior Met Coal to $123 From $117, Keeps Buy Rating

MT Newswires Live
·
Jun 10

Warrior Met Coal Chief Administrative Officer Kelli K. Gant sells 20,000 shares for $2.2 million

Reuters
·
Jun 05

RBC Capital Reaffirms Their Hold Rating on Warrior Met Coal (HCC)

TIPRANKS
·
Jun 04

ABBISKO-B Presents Innovative Modeling Framework for ABSK-011 in HCC at PAGE Conference

Stock News
·
Jun 04

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

Dow Jones
·
May 28

Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC

GlobeNewswire
·
May 27

Assessing Warrior Met Coal (HCC) Valuation After Recent Share Price Softness And Blue Creek Growth Plans

Simply Wall St.
·
May 27

Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma

GlobeNewswire
·
May 21

Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market

GlobeNewswire
·
May 18

A Look At Warrior Met Coal (HCC) Valuation After Early Blue Creek Spend And Strong Q1 Results

Simply Wall St.
·
May 18

Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy

GlobeNewswire
·
May 13

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

GlobeNewswire
·
May 13

A Look At Warrior Met Coal (HCC) Valuation As Long Term Returns Outpace Recent Share Price Moves

Simply Wall St.
·
May 09

Is It Time To Reassess Warrior Met Coal (HCC) After Its Recent Share Price Pullback

Simply Wall St.
·
May 06

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

GlobeNewswire
·
May 05

Warrior Met Coal Is Maintained at Buy by UBS

Dow Jones
·
May 02